tuneTypical Dose
200–500 mg per day (UMP) or 25 mg (TAU)
Natural Compound
Uridine
Uridine monophosphate (UMP) / Uridine-5'-monophosphate
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
4-8 weeks for structural neurological benefits.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Uridine is a nucleoside involved in RNA synthesis and phospholipid production. It is used for neuronal membrane and synapse support goals, often combined with choline and omega-3 fatty acids.
Nutritional intervention evidence suggests uridine combined with choline and DHA can support synapse-related biomarkers and cognitive measures in early Alzheimer’s nutrition formulas. Standalone evidence is limited. Minority research explores mood and dopaminergic signaling effects and neuropathic pain outcomes, with sparse data. Benefits likely depend on complementary nutrients and specific clinical contexts rather than isolated uridine use.
Pyrimidine nucleoside that crosses the BBB and is converted into CDP-choline via the Kennedy pathway, serving as a rate-limiting substrate for phosphatidylcholine synthesis in neuronal membranes. Enhances neurite outgrowth, synaptogenesis, and may modulate dopamine receptor density.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Supports synaptic membrane synthesis via the CDP-choline pathway (strong animal evidence)
- May enhance dopaminergic tone and mood (preclinical antidepressant-like effects)
Secondary Outcomes
- Increased dendritic spine density and synaptic protein levels in animal models
- Potential cognitive enhancement when combined with DHA and choline (mechanistic basis, limited human data)
Safety
Contraindications and Interactions
Contraindications
- 5-FU or capecitabine chemotherapy (pharmacological interaction with pyrimidine pathway)
Side effects
- GI upset
- Diarrhea (dose-dependent, generally mild)
Interactions
- 5-fluorouracil (5-FU), direct pharmacological interaction. Uridine triacetate is FDA-approved as 5-FU antidote
Avoid if
- Undergoing fluoropyrimidine-based chemotherapy
Evidence
Study-level References
uridine-SRC-001Animal Study / Mechanistic basis for human trials
Sourceopen_in_newWurtman RJ, et al. "Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally." Brain Res. 2006.
Population: Gerbils
Dose protocol: Uridine + DHA administered orally
Key findings: Oral administration of Uridine and DHA significantly increased the levels of major synaptic proteins and membrane phospholipids, demonstrating true promotion of synaptogenesis.
Paper content
Oral administration of Uridine and DHA significantly increased the levels of major synaptic proteins and membrane phospholipids, demonstrating true promotion of synaptogenesis.
uridine-SRC-002Animal Study
Sourceopen_in_newCarlezon WA Jr, et al. "Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats." Biol Psychiatry. 2005.
Population: Rats
Dose protocol: Uridine and omega-3 fatty acids, alone and combined
Key findings: Uridine produced antidepressant-like effects in the forced swim test, and these effects were potentiated when combined with omega-3 fatty acids, supporting the membrane phospholipid synthesis hypothesis.
Paper content
Uridine produced antidepressant-like effects in the forced swim test, and these effects were potentiated when combined with omega-3 fatty acids, supporting the membrane phospholipid synthesis hypothesis.
uridine-SRC-003Review / Mechanistic characterization
Sourceopen_in_newWurtman RJ. "Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents." Metabolism. 2008.
Population: N/A (review)
Dose protocol: N/A
Key findings: Characterized the Kennedy (CDP-choline) pathway by which uridine, DHA, and choline act as rate-limiting substrates for phosphatidylcholine synthesis in neuronal membranes. Provided the mechanistic rationale for the uridine + DHA + choline combination.
Paper content
Characterized the Kennedy (CDP-choline) pathway by which uridine, DHA, and choline act as rate-limiting substrates for phosphatidylcholine synthesis in neuronal membranes. Provided the mechanistic rationale for the uridine + DHA + choline combination.
uridine-SRC-004Systematic review and meta-analysis of 4 clinical trials.
Sourceopen_in_newShim YS, Yoon B, Na S, Lim EY, Hong YJ, Yang DW. A systematic review and meta-analysis of the clinical effects of Souvenaid in patients with Alzheimer's disease. Asia Pac J Clin Nutr. 2021;30(1):30-41. doi:10.6133/apjcn.202103_30(1).0005. PMID:33787038.
Population: Patients with Alzheimer's disease across four clinical trials of Souvenaid.
Dose protocol: Souvenaid (multi-nutrient drink with UMP, DHA, choline) in Alzheimer's disease trials.
Key findings: No significant effects on cognition, functional ability, or global clinical change across four pooled trials.
Notes: Important limit-setting meta-analysis. Preclinical promise of uridine combinations has not translated into consistent cognitive benefits in AD.
Paper content
This systematic review and meta-analysis evaluated four clinical trials of Souvenaid (a multi-nutrient drink containing uridine monophosphate, DHA, choline, and other ingredients) in patients with Alzheimer's disease. The analysis found no significant effects on cognition, functional ability, or global clinical change. This is a limit-setting study for uridine-containing formulations. While Souvenaid is a multi-ingredient product and uridine cannot be isolated as the driver, the null result across four trials is important context for anyone citing the Kennedy pathway rationale. The preclinical promise of uridine combinations has not translated into consistent cognitive benefits in Alzheimer's trials.
uridine-SRC-005Post-hoc analysis of a randomized controlled trial (LipiDiDiet).
Sourceopen_in_newHendrix SB, Soininen H, Solomon A, et al. Combined Evidence for a Long-Term, Clinical Slowing Effect of Multinutrient Intervention in Prodromal Alzheimer's Disease: Post-Hoc Analysis of 3-Year Data from the LipiDiDiet Trial. J Prev Alzheimers Dis. 2023;10(3):464-470. doi:10.14283/jpad.2023.29. PMID:37357286.
Population: Adults with prodromal Alzheimer's disease.
Dose protocol: Fortasyn Connect (Souvenaid with UMP, DHA, EPA, choline) vs placebo for 36 months.
Key findings: Multinutrient intervention associated with significantly less clinical decline over 36 months in prodromal AD across all outcome measures.
Notes: Post-hoc analysis of LipiDiDiet RCT. Most positive long-term dataset for uridine-containing formulation, but multi-ingredient design prevents uridine attribution.
Paper content
This post-hoc analysis of the LipiDiDiet RCT examined 3-year outcomes of Fortasyn Connect (Souvenaid, containing uridine monophosphate, DHA, EPA, choline, and other nutrients) versus placebo in prodromal Alzheimer's disease. Using multiple statistical approaches, the analysis found that the multinutrient intervention was associated with significantly less clinical decline over 36 months across all outcome measures. This is the most positive long-term human dataset for a uridine-containing formulation, though the multi-ingredient design prevents attributing effects specifically to uridine. The prodromal AD population also limits generalization to healthy cognitive-enhancement contexts.